Acitretin in psoriasis: An overview of adverse effects

被引:130
作者
Katz, HI
Waalen, J
Leach, EE
机构
[1] Univ Minnesota, Dept Dermatol, Fridley, MN 55432 USA
[2] Univ Calif San Diego, San Diego State Univ, Prevent Med Residency Program, San Diego, CA 92103 USA
[3] Roche Labs Inc, Dermatol, Nutley, NJ USA
关键词
D O I
10.1016/S0190-9622(99)70359-2
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Oral retinoids are among the drugs of choice for pustular and erythrodermic psoriasis. In addition, retinoids are effective in combination with other topical and systemic agents for the treatment of plaque-type psoriasis. Acitretin, the active retinoid metabolite, has replaced etretinate in retinoid therapy of psoriasis because of its more favorable pharmacokinetic profile, including a significantly shorter half-life. Retinoids, including acitretin, are potent teratogens, leading to strict requirements for pregnancy prevention during and after their use. Other retinoid side effects are generally preventable or manageable through proper patient selection, dose adjustments, and routine monitoring. Mucocutaneous side effects such as cheilitis and hair loss are the most common dose-dependent side effects, requiring dose reduction in some patients. Less common effects such as hepatotoxicity, serum lipid alterations, pancreatitis, and possible skeletal effects are also discussed.
引用
收藏
页码:S7 / S12
页数:6
相关论文
共 27 条
[1]   ACITRETIN (RO10-1670) AND ORAL-CONTRACEPTIVES - INTERACTION STUDY [J].
BERBIS, P ;
BUN, H ;
GEIGER, JM ;
ROGNIN, C ;
DURAND, A ;
SERRADIMIGNI, A ;
HARTMANN, D ;
PRIVAT, Y .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1988, 280 (06) :388-389
[2]   OVERVIEW OF RECENT CLINICAL PHARMACOKINETIC STUDIES WITH ACITRETIN (RO 10-1670, ETRETIN) [J].
BRINDLEY, CJ .
DERMATOLOGICA, 1989, 178 (02) :79-87
[3]   A POTENTIALLY NEW METABOLIC PATHWAY - ETHYL ESTERIFICATION OF ACITRETIN [J].
CHOU, RC ;
WYSS, R ;
HUSELTON, CA ;
WIEGAND, UW .
XENOBIOTICA, 1992, 22 (08) :993-1002
[4]   Severe limb defects and craniofacial anomalies in a fetus conceived during acitretin therapy [J].
deDieSmulders, CEM ;
Sturkenboom, MCJM ;
Veraart, J ;
vanKatwijk, G ;
Sastrowijoto, P ;
VanderLinden, E .
TERATOLOGY, 1995, 52 (04) :215-219
[5]   ETRETINATE - PERSISTENT SERUM LEVELS AFTER LONG-TERM THERAPY [J].
DIGIOVANNA, JJ ;
ZECH, LA ;
RUDDEL, ME ;
GANTT, G ;
PECK, GL .
ARCHIVES OF DERMATOLOGY, 1989, 125 (02) :246-251
[6]   ACITRETIN AND ETRETINATE - HOW AND WHEN THEY SHOULD BE USED [J].
GEIGER, JM ;
SAURAT, JH .
DERMATOLOGIC CLINICS, 1993, 11 (01) :117-129
[7]   Oral retinoids - Efficacy and toxicity in psoriasis [J].
Gollnick, HPM .
BRITISH JOURNAL OF DERMATOLOGY, 1996, 135 :6-17
[8]   SIDE-EFFECT PROFILE OF ACITRETIN THERAPY IN PSORIASIS [J].
GUPTA, AK ;
GOLDFARB, MT ;
ELLIS, CN ;
VOORHEES, JJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1989, 20 (06) :1088-1093
[9]  
KATZ HI, 1998, GUIDE ADVERSE TREATM, P8
[10]  
Lammer E J, 1988, Prog Clin Biol Res, V281, P193